Cancer Biomarkers Market Research Report 2017-2022

DUBLIN, October 11, 2017 /PRNewswire/ --

The "Cancer Biomarkers Market by Type, Cancer Type, Profiling Technology, Application - Global Forecast to 2022" report has been added to Research and Markets' offering.

The global cancer biomarkers market is projected to reach USD 20.48 Billion by 2022 from USD 11.53 Billion in 2017, at a CAGR of 12.2%.

Major factors driving the growth of the market are rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies. However, the high cost of various cancer diagnostic tests, need for high capital investments, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection are restricting the growth of this market. In this report, the global cancer biomarker market is segmented on the basis of biomarker type, cancer type, profiling technology, application, and region.

The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin's lymphoma, kidney, and other cancers. In 2017, the breast cancer segment is expected to account for the largest share of the global market by cancer type. The large share of this segment is mainly attributed to the high prevalence of breast cancer over the last few years, increased awareness about breast cancer diagnosis, and increasing research focus on breast cancer.

On the basis of biomarker type, the cancer biomarkers market segmented into protein biomarker, genetic biomarker, and other biomarkers. In 2017, the protein biomarkers segment is expected to account for the largest share of the global market for cancer biomarkers. The large share of this segment is mainly attributed to the tremendous potential of protein biomarkers in cancer detection, diagnostics, prognostics, and clinical & therapeutic applications; and low cost of the protein biomarker tests as compared to genetic biomarker tests. The increasing focus of pharmaceutical companies towards the discovery of protein biomarkers is further expected to fuel the growth of this market during the forecast period.

On the basis of application, the cancer biomarkers market is classified into diagnostics, research and development, prognostics, risk assessment, and other applications. In 2017, the diagnostics segment is expected to account for largest share of the global market for cancer biomarkers. The large share of this segment is mainly attributed to the rising incidences of cancer, increased awareness, and acceptance of diagnostic tests, technological advancements, and the need for early-stage cancer diagnosis.

The cancer biomarkers market on the basis of profiling technology is classified into omics technology, imaging technology, immunoassay, bioinformatics, and cytogenetics. The omics technologies segment is expected to account for the largest share of the global market for cancer biomarkers in 2017. The demand for advanced omics technologies has increased significantly in recent years mainly due to the high-throughput nature of these technologies. This trend is expected to continue to drive the market in the coming years.

The cancer biomarkers market is dominated by established players such as Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), Qiagen (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), and Hologic (US).

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Cancer Biomarkers Market, By Biomarker Type

7 Cancer Biomarker Market, By Cancer Type

8 Cancer Biomarkers Market, By Profiling Technology

9 Cancer Biomarkers Market, By Application

10 Cancer Biomarkers Market, By Region

11 Competitive Landscape

12 Company Profiles

• Abbott Laboratories
• Agilent Technologies
• Becton, Dickinson and Company
• Bio-Rad Laboratories
• Biomrieux SA
• Danaher Corporation
• GE Healthcare
• Hologic
• Illumina
• Merck & Co.
• Myriad Genetics
• Qiagen N.V.
• Quest Diagnostics
• Roche Diagnostics
• Sysmex Corporation
• Thermo Fisher Scientific

For more information about this report visit https://www.researchandmarkets.com/research/khcz7w/cancer_biomarkers

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716